APA (7th ed.) Citation

T, S., J, M., M, I., P, P., T, O., K, F., & T, H. (2025). Co-expression of CD30 and SLFN11 serves as a dual biomarker for the treatment of cutaneous T-cell lymphoma. NAR cancer, 7(4), zcaf037. https://doi.org/10.1093/narcan/zcaf037

Chicago Style (17th ed.) Citation

T, Shimauchi, Murai J, Iwasaki M, Phadungsaksawasdi P, Ojima T, Fujii K, and Honda T. "Co-expression of CD30 and SLFN11 Serves as a Dual Biomarker for the Treatment of Cutaneous T-cell Lymphoma." NAR Cancer 7, no. 4 (2025): zcaf037. https://doi.org/10.1093/narcan/zcaf037.

MLA (9th ed.) Citation

T, Shimauchi, et al. "Co-expression of CD30 and SLFN11 Serves as a Dual Biomarker for the Treatment of Cutaneous T-cell Lymphoma." NAR Cancer, vol. 7, no. 4, 2025, p. zcaf037, https://doi.org/10.1093/narcan/zcaf037.